Development & Licensing Team

Dr. Stephen Donahue has been with Ore Pharmaceuticals since 2007 and is responsible for leading the Company’s clinical development program. His background includes all phases of clinical drug development and regulatory affairs. He has achieved board certifications in both Internal Medicine and Clinical Pharmacology. Previously, Dr. Donahue was VP, Clinical Research and Operations at Epix Pharmaceuticals, where he headed the pharmaceutical clinical development, clinical operations and regulatory affairs. Before Epix, Dr. Donahue served with Merck & Co., Inc. as Medical Director, Clinical Research, Atherosclerosis and Metabolism. He also held positions of increasing responsibility with Bristol-Myers Squibb in the departments of Clinical Design/Evaluation, and Clinical Pharmacology/ Experimental Medicine. He has developed drugs in several different therapeutic areas and has worked on products such as Vytorin®, Pravachol®, and Glucophage®. Dr. Donahue holds an M.D. from Georgetown University, and was an NIH Fellow in Clinical Pharmacology at Georgetown University Medical Center.

Mr. Larry Tiffany has served as Interim Head, Commercial Operations, Ore Pharmaceuticals Inc. and President and Chief Executive Officer, DioGenix Inc. since December 2007. He was previously Senior Vice President, General Manager, Genomics. Prior to returning to the Company, Mr. Tiffany was President and Chief Business Officer of Genetraks, an Australian-based veterinary molecular diagnostics firm. Prior to joining Genetraks, Mr. Tiffany was VP, Worldwide Business Development for Gene Logic. Mr. Tiffany holds a J.D. degree from Franklin Pierce Law Center and a M.S. in Biotechnology from The Johns Hopkins University.

Ms. Deborah Barbara is Vice President of Business Development & Licensing at Ore Pharmaceuticals. She possesses over 20 years of experience in pharmaceutical, diagnostic and research tool business development and licensing. In her current role, Ms. Barbara is responsible for the sourcing and expansion of drug repositioning partnerships and the out-licensing of Ore Pharmaceuticals’ Drug Repositioning Program assets. Prior to joining the Company, Ms. Barbara served as the Senior Director for Licensing and Technology Development at the Johns Hopkins University. In this role, she was responsible for all aspects of the department’s interactions with industry, including the drafting and negotiation of license, collaboration and research agreements to support the University’s research and technology development initiatives. Prior to this, she held a variety of positions of increasing responsibility at Amersham Life Sciences in sales, marketing, and technology transfer/access supporting the pharmaceutical industry. Ms. Barbara holds an M.B.A. from Loyola College.

Mr. John A. Herrmann III is Vice President of Strategic Alliances and Licensing as well as Ore Pharmaceuticals’ business counsel. He has been a member of the business development and licensing teams that negotiated and executed the drug repositioning agreements with all of Ore Pharmaceuticals’ current pharmaceutical partners. Prior to joining the Company, he held counsel positions at several biotechnology and healthcare companies, including four years as senior business counsel at Celera Genomics and eight years at Baxter Healthcare Corporation. Mr. Herrmann earned his J.D. at the University of Illinois.

Mr. Christopher Comrack is a member of the clinical development team and is responsible for helping to define the clinical development strategy and articulate, execute and plan clinical development activities for internal clinical development programs. In addition, Mr. Comrack is a member of the business development and licensing team and is responsible for the development of financial terms, business structure and for negotiating outlicenses to Ore Pharmaceuticals’ intellectual property and associated assets. Prior to joining the Company, he was the Senior Manager of Business Development and Marketing at Beth Israel Deaconess Medical Center in the Technology Ventures Office. There he was responsible for strategic alliance development and technology marketing and licensing. Previously, Mr. Comrack was the Manager of Scientific Development for Millennium Pharmaceuticals. In this position he structured and negotiated collaborative agreements and managed academic relationships. Mr. Comrack holds an M.B.A. from F.W. Olin Graduate School of Business at Babson College.